See more : Arakawa Chemical Industries, Ltd. (4968.T) Income Statement Analysis – Financial Results
Complete financial analysis of Codex DNA, Inc. (DNAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codex DNA, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Nano-X Imaging Ltd. (NNOX) Income Statement Analysis – Financial Results
- Beryl Drugs Limited (BERLDRG.BO) Income Statement Analysis – Financial Results
- Hangzhou IECHO Science & Technology Co., Ltd. (688092.SS) Income Statement Analysis – Financial Results
- Charter Hall Social Infrastructure REIT (CQE.AX) Income Statement Analysis – Financial Results
- Beijing Shougang Co., Ltd. (000959.SZ) Income Statement Analysis – Financial Results
Codex DNA, Inc. (DNAY)
About Codex DNA, Inc.
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 27.44M | 11.04M | 6.58M |
| Cost of Revenue | 11.84M | 6.74M | 2.95M |
| Gross Profit | 15.60M | 4.30M | 3.63M |
| Gross Profit Ratio | 56.84% | 38.93% | 55.12% |
| Research & Development | 23.46M | 14.55M | 8.93M |
| General & Administrative | 22.13M | 14.23M | 4.13M |
| Selling & Marketing | 16.49M | 10.90M | 6.93M |
| SG&A | 38.62M | 25.13M | 11.06M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 62.08M | 39.67M | 19.99M |
| Cost & Expenses | 73.92M | 46.42M | 22.94M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.22M | -1.37M | 690.00K |
| Depreciation & Amortization | 3.23M | 908.00K | 1.46M |
| EBITDA | -46.49M | -39.41M | -15.86M |
| EBITDA Ratio | -169.44% | -356.83% | -241.15% |
| Operating Income | -49.71M | -40.31M | -16.36M |
| Operating Income Ratio | -181.20% | -365.05% | -248.80% |
| Total Other Income/Expenses | -1.96M | -3.57M | -1.64M |
| Income Before Tax | -48.45M | -38.94M | -18.01M |
| Income Before Tax Ratio | -176.59% | -352.66% | -273.80% |
| Income Tax Expense | -24.00K | 14.00K | 5.00K |
| Net Income | -48.42M | -38.96M | -18.01M |
| Net Income Ratio | -176.50% | -352.78% | -273.87% |
| EPS | -1.64 | -1.83 | -0.84 |
| EPS Diluted | -1.64 | -1.83 | -0.84 |
| Weighted Avg Shares Out | 29.46M | 21.32M | 21.32M |
| Weighted Avg Shares Out (Dil) | 29.46M | 21.32M | 21.32M |
Codex DNA to Present at the Jefferies London Healthcare Conference
Codex DNA to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q2 2021 Results - Earnings Call Transcript
Codex DNA Reports Second Quarter 2021 Financial Results
Codex DNA Shares Move Higher On Licensing, Supply Deal With TriLink For mRNA Capping Tech
Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology
Codex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Codex DNA Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports